The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Ips competitive analysis

Loading summary...

Latest oppositions filed by Ips

Explore patent oppositions filed by Ips against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Nov 13, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP4161562
High Dose And Low Volume Botulinum Toxin Treatment Of Facial WrinklesMERZ PHARMAAug 20, 2025
EP3533424
Systems And Methods For Controlling PositionADVANCED BRAIN MONITORINGJun 27, 2025
EP2622675
Redox Flow Batteries Based On Supporting Solutions Containing ChlorideBATTELLE MEMORIAL INSTITUTEJun 23, 2025
EP3835020
HoseSAINT GOBAINMay 26, 2025
EP3271308
Plaster-Based Acoustic PanelSAINT GOBAINMay 7, 2025
EP3755769
Functional Fluids Comprising Low-Viscosity Polyalpha-Olefin Base StockEXXONMOBIL CHEMICAL PATENTSApr 24, 2025
EP4130138
Polyethylene Copolymer Composition For A Film LayerBOREALISJul 3, 2024
EP4059904
A Process For The Continuous Preparation Of Alpha-Calcium Sulphate Hemihydrate And A Particulate GypsumSAINT GOBAINJun 5, 2024
EP3368071
Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic EffectREVANCE THERAPEUTICSOct 26, 2022
EP3017120
Dry Construction System For Making Partition Walls, Suspended Ceilings Or The Like, Carrier Profile Therefor, And Use Of This Dry Construction SystemSAINT GOBAINJul 28, 2022

Latest patents of Ips opposed by its competitors

Explore Ips's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP3796929
Sep 18, 2024Suppression Of Bone Cancer-Induced Allodynia1
EP3758611
Jul 24, 2024Use Of Ultrasound To Guide Injection Of Non-Cytotoxic Protease1
EP3266456
May 5, 2021Combinations Of Liposomal Irinotecan, 5-Fu And Leucovorin For The Treatment Of Pancreatic Cancer3
EP3337467
Dec 9, 2020Combination Therapy Using Liposomal Irinotecan And A Parp Inhibitor For Cancer Treatment1
EP3337478
Aug 12, 2020Methods For Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan And Oxaliplatin2
EP2664343
Dec 18, 2019Suppression Of Cancer1
EP2939688
Feb 20, 2019Pharmaceutical Compositions Comprising Botulinum Neurotoxin1
EP2957278
May 17, 2017A Stable Composition Comprising Pthrp And Uses Thereof2
EP2677029
May 10, 2017Methods For The Manufacture Of Proteolytically Processed Polypeptides1
EP2861210
May 3, 2017Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan1

Latest PTAB cases involving Ips

Discover the latest PTAB cases involving Ips, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 14, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Ips

IPR2025-01531Sep 12, 2025APOTEXIPSEN BIOPHARMPending
IPR2025-00505Jan 17, 2025CSPC PHARMACEUTICAL GROUPIPSEN BIOPHARMTrial Instituted
IPR2016-01144Jun 3, 2016DUNCAN PARKINGIPS GROUPInstitution Denied
IPR2016-01145Jun 3, 2016DUNCAN PARKINGIPS GROUPInstitution Denied
IPR2016-00067Oct 22, 2015DUNCAN PARKINGIPS GROUPFinal Written Decision
IPR2016-00068Oct 22, 2015DUNCAN PARKINGIPS GROUPInstitution Denied
IPR2016-00069Oct 22, 2015DUNCAN PARKINGIPS GROUPInstitution Denied
IPR2016-00070Oct 22, 2015DUNCAN PARKINGIPS GROUPInstitution Denied

Peer Comparison New

IP litigation analysis comparing Ips with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
IPSEN - 1 - -
IVA SCHMETZ1 - - -